Catheter Precision Stock Price, News & Analysis

Catheter Precision (NYSE American: VTAK) announced expanded hospital evaluations and approvals for its LockeT suture retention device and reports its highest recorded January revenue. The company highlighted new U.S. high-volume center evaluations, international market entries including CE Mark activity, and an expected strong Q1 2026 adoption driven by workflow and cost benefits.

Management named several hospitals undergoing evaluations and cited faster staff onboarding, same-day discharge potential, and continued European penetration as adoption drivers.

Catheter Precision (NYSE/American: VTAK) announced receipt of its first LockeT purchase order in Germany from Universitätsklinikum Frankfurt on January 22, 2026. The order marks LockeT's official entry into the German market and installs the company's suture retention device designed to improve workflow after venous catheter access while remaining cost effective. Catheter Precision cited Germany as the largest healthcare market in Europe and referenced a $900 million German electrophysiology devices market size for 2024. The Frankfurt university hospital will act as a reference site as the company scales operations across Germany and broader Europe.

Catheter Precision (NYSE American: VTAK) received a VIVO purchase order from University Clinical Center Ljubljana, a leading public hospital in Slovenia, expanding the company’s global commercial footprint to 15 countries. The company said the order and recent entries validate VIVO and LockeT adoption by physicians and follow a year of growth driven by distribution partnerships and ongoing navigation of international regulatory processes as it pursues further expansion in 2026.

Catheter Precision (NYSE:VTAK) announced on Dec 18, 2025 the first purchase order and a multi‑year commitment for its LockeT device at Mater Private Hospital in Dublin, Ireland. Mater Private is described as Ireland's largest electrophysiology center, performing over 1,000 EP procedures annually. The company said LockeT was rapidly adopted during onboarding, with 52 staff trained in two days, and that a European key opinion leader helped introduce the device. The agreement represents an initial commercial expansion into an eighth European country following CE mark receipt and supports the company's international adoption strategy.

Catheter Precision (NYSE American: VTAK) announced that its VIVO system secured a significant multi-year tender at Albert Szent-Györgyi Health Centre (Szeged University Hospital) in Hungary, marking the company’s first installation in Hungary and a push into Central and Eastern Europe. The award was won in partnership with local distributor Fototronic. Installation is anticipated in Q1 2026. The release positions the VIVO system — a non-invasive 3D ventricular tachycardia localization tool used before ablation — as gaining wider adoption following recent multi-year agreements in France, supporting the company’s European expansion strategy.

Catheter Precision (NYSE/American: VTAK) announced the commercial launch of its LockeT suture retention device in Switzerland on December 1, 2025. The first clinical cases were performed at Spitalzentrum Biel under PD Dr. Rainer Zbinden with reported excellent procedural outcomes and positive staff feedback.

The launch follows a strategic distribution agreement with FuMedica AG, enabling rollout to hospitals and clinics across Switzerland and expanding Catheter Precision’s European footprint. The company noted over 10,000 LockeT units shipped globally and highlighted benefits including reduced groin management costs and support for same-day discharge.

Catheter Precision (NYSE:VTAK) said the Centers for Medicare and Medicaid services will add electrophysiology ablation codes to the ASC-Covered Procedures List effective January 1, 2026, a policy change that expands Medicare beneficiary access to EP services in ambulatory surgery centers.

The company framed the change as a new commercialization opportunity for its LockeT suture retention device, saying ASCs seek cost‑effective, workflow‑improving products that enable same‑day discharge and quick hemostasis. The announcement highlights potential for additional patient scheduling and new ASC facilities to adopt LockeT.

Catheter Precision (NYSE:VTAK) announced rapid commercial uptake of its LockeT closure device in South Africa on Nov 20, 2025. With distributor HLC Medical and Dr. Heather Henry-Lines, LockeT was implemented in five hospitals within two months; three hospitals use LockeT daily and two use it routinely. Two additional hospitals are awaiting internal approvals. All five hospitals have placed reorders through the distributor. Management highlighted LockeT as cost effective, workflow-improving, and supportive of rapid hemostasis enabling same-day discharge.

Catheter Precision (NYSE American: VTAK) reported Q3 2025 revenue of $226,000, up 135% vs Q3 2024, and nine-month revenue of $581,000, up 114% vs YTD 2024.

GAAP net loss for Q3 2025 was $2,251,000, a 45% reduction from Q3 2024; nine-month GAAP net loss was $11,405,000 vs $11,015,000 year‑earlier. Non‑cash charges were $4,232,000 for the nine months.

Commercially, the company cited a Q2 CE Mark for LockeT, growing international interest (Germany, France, Italy, Spain, Portugal, UK, South Africa), five South Africa reorders in October, and the first VIVO purchase order from France. Management said two VIVO clinical studies completed in 2025 delivered clinical evidence supporting VIVO's clinical potential.